Skip to search formSkip to main contentSkip to account menu

CC 10004

Known as: CC-10004, CC10004 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apremilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
OBJECTIVE To review the pharmacology, efficacy, and safety of apremilast and determine its role relative to other agents in the… 
2012
2012
Apremilast: a step forward in the treatment of psoriasis?
2009
2009
CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease.
Review
2007
Review
2007
Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis.
The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including… 
Review
2005
Review
2005
CC-10004 .
CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential… 
2004
2004
The effects of selective cytokine inhibitory drugs (CC‐10004 and CC‐1088) on VEGF and IL‐6 expression and apoptosis in myeloma and endothelial cell co‐cultures
Myeloma cells and human umbilical vein endothelial cells (HUVECs) were co‐cultured to model in vitro the interactions between… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)